Bellevue Life Sciences Acquisition (BLACW) Stock Price, News & Analysis

Company Overview

Bellevue Life Sciences Acquisition Corp. is a Delaware-incorporated blank-check company formed for the purpose of effecting a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination with one or more businesses in the life sciences sector. Trading on the Nasdaq under the symbol BLACW, the company seeks to leverage public markets to support growing biopharmaceutical, medical device and health-technology enterprises.

The firm is sponsored by Bellevue Life Sciences, a global investment firm focused exclusively on life sciences and healthcare. Through this sponsorship, the acquisition company benefits from Bellevue’s deep industry network, scientific expertise and deal-sourcing capabilities. The sponsor’s mandate is to identify high-potential private companies with strong management teams, differentiated products or platforms and clear pathways to commercial scale or additional clinical validation.

Bellevue Life Sciences Acquisition’s leadership team comprises professionals with extensive experience in biotechnology investment, pharmaceutical R&D and capital markets. While the SPAC has yet to announce a definitive business combination, its advisors and executives draw on decades of sector knowledge, having supported numerous clinical-stage ventures and public offerings within the life sciences ecosystem.

Targeting businesses across North America, Europe and selected Asian markets, the acquisition company intends to focus on opportunities that address significant unmet medical needs or promising platform technologies. By combining private-company growth ambitions with public-market capital and governance, Bellevue Life Sciences Acquisition aims to accelerate the development of innovative therapies and technologies for patients worldwide.

Key Stats

• Today's Range: $0.04 to $0.04
• 50-Day Range: $0.04 to $0.07
• 52-Week Range: $0.01 to $0.10
• Volume: 3,750 shs
• Average Volume: 55,965 shs
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

BLACW Stock Analysis - Frequently Asked Questions

How have BLACW shares performed this year?

Bellevue Life Sciences Acquisition's stock was trading at $0.0479 at the start of the year. Since then, BLACW shares have decreased by 16.5% and is now trading at $0.04.

How do I buy shares of Bellevue Life Sciences Acquisition?

Shares of BLACW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Financial Services
• Industry: Shell Companies
• Sub-Industry: N/A
• Current Symbol: NASDAQ:BLACW
• CIK: 1840425
• Web: N/A
• Phone: 425-635-7700
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A